Lidocaine has been reported to inhibits hepatocellular carcinoma development via regulating miR-421/CPEB3 pathway [37], and inhibits glioma cell proliferation, migration and invasion via regulating the circEZH2/miR-181b-5p axis [38]. Here, CPEB3 is linked to hepatocellular carcinoma.